27 octubre 2008

Yondelis en Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus . NCI y Goc Verifican Fase II

Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus

This study is currently recruiting participants.

Verified by National Cancer Institute (NCI), October 2008
Sponsors and Collaborators: Gynecologic Oncology Group
National Cancer Institute (NCI)


Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00379145
Estimated Enrollment: 43
Study Start Date: June 2007
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Investigators
Study Chair: Bradley J. Monk, MD Chao Family Comprehensive Cancer Center
Last Updated: October 22, 2008